Belinda J. Schouten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Belinda J. Schouten has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Penelope J Hunt
2 shared publicationsChris M. Frampton
Department of Medicine (C.M.F.), Christchurch School of Medicine and Health Sciences, Christchurch 8011, New Zealand
1 shared publication- Eric A. Espiner
Department of Endocrinology, Christchurch Hospital, Private Bag 4710, Christchurch, New Zealand
1 shared publication John H. Livesey
Department of Endocrinology (B.J.S., P.J.H., J.H.L., S.G.S.), Christchurch Hospital, Christchurch 8011, New Zealand
1 shared publicationMark Richards
1 shared publicationMatthew P Doogue
Department of Endocrinology, Christchurch Public Hospital, Christchurch, New Zealand
1 shared publication
Latest Publications
- 1 June 2011
- Published by The Endocrine Society
- p. P2-109
CNP Forms in Adult Hyperthyroidism: Correlation with Thyroid Hormones and Markers of Bone Turnover
C-type natriuretic peptide (CNP) is a paracrine hormone that is essential for normal endochondral bone growth. Although in vitro studies also show that CNP increases osteoblastogenesis (1), its role in bone remodelling is unclear. Using assays of amino terminal proCNP (NTproCNP), a bio-inactive product of CNP gene expression readily measurable in plasma, we have shown that levels strongly correlate with linear growth velocity in children (2), and with growth plate width in rodent pups. Consistent with these findings, plasma NTproCNP correlates with growth velocity and with change in thyroid hormone levels (3) during corrective treatment of children with acquired thyroid disorders. Whether CNP production is responsive to change in thyroid status, or change in bone turnover rates, after growth plate closure has not been studied. Accordingly we have studied changes in CNP production in adult subjects presenting with hyperthyroidism-a condition where both bone formation and resorption rates are enhanced. In 20 (19 female) subjects (mean age 43yr), plasma concentrations of thyroid hormones (T3 and T4), CNP and NTproCNP, and markers of bone resorption (CTx) and formation (bALP, osteocalcin and PINP) were measured at regular intervals over 24 weeks as euthyroid status was restored by thionamide treatment. At presentation (baseline), plasma NTproCNP was strongly correlated with T3 (r=0.48, p=0.03) and free T4 index (r=0.54, p=0.01). For all time points, plasma CNP and NTproCNP were highly correlated (r=0.7, p<0.0001) and both peptides correlated strongly with CTx (r=0.53, p<0.0001 and r=0.64, p<0.0001 respectively). During treatment, plasma NTproCNP declined progressively and was positively correlated with change in T3 (r=0.68, p=0.001). Associations of NTproCNP, T3 and CTx with other bone markers (PINP, osteocalcin, bALP) were weaker and reflected the latter's variable temporal responses after normal levels of thyroid hormones were restored (ie after 4-6 weeks). We conclude that, as in the immature skeleton, CNP production is linked to thyroid hormone levels in adults. The close coupling of T3, NTproCNP and CTx during changes in bone turnover suggests that CNP acts to maintain skeletal integrity in the face of T3-dependent bone resorption but participates less in later phases involving bone mineral accrual. (1) Hagiwara H et al., Am J Physiol 1996; 270:C1311-1318 (2) Prickett TC et al., Pediatr Res 2005; 58:334-340 (3) Reh CS et al., Program of the 91st Annual Meeting of the Endocrine Society, Washington, DC, 2009; Poster 03-342 Nothing to Disclose: BJS, TCP, PJH, MR, EAE
- 1 June 2011
- Published by The Endocrine Society
- p. P2-109
CNP Forms in Adult Hyperthyroidism: Correlation with Thyroid Hormones and Markers of Bone Turnover
C-type natriuretic peptide (CNP) is a paracrine hormone that is essential for normal endochondral bone growth. Although in vitro studies also show that CNP increases osteoblastogenesis (1), its role in bone remodelling is unclear. Using assays of amino terminal proCNP (NTproCNP), a bio-inactive product of CNP gene expression readily measurable in plasma, we have shown that levels strongly correlate with linear growth velocity in children (2), and with growth plate width in rodent pups. Consistent with these findings, plasma NTproCNP correlates with growth velocity and with change in thyroid hormone levels (3) during corrective treatment of children with acquired thyroid disorders. Whether CNP production is responsive to change in thyroid status, or change in bone turnover rates, after growth plate closure has not been studied. Accordingly we have studied changes in CNP production in adult subjects presenting with hyperthyroidism-a condition where both bone formation and resorption rates are enhanced. In 20 (19 female) subjects (mean age 43yr), plasma concentrations of thyroid hormones (T3 and T4), CNP and NTproCNP, and markers of bone resorption (CTx) and formation (bALP, osteocalcin and PINP) were measured at regular intervals over 24 weeks as euthyroid status was restored by thionamide treatment. At presentation (baseline), plasma NTproCNP was strongly correlated with T3 (r=0.48, p=0.03) and free T4 index (r=0.54, p=0.01). For all time points, plasma CNP and NTproCNP were highly correlated (r=0.7, p<0.0001) and both peptides correlated strongly with CTx (r=0.53, p<0.0001 and r=0.64, p<0.0001 respectively). During treatment, plasma NTproCNP declined progressively and was positively correlated with change in T3 (r=0.68, p=0.001). Associations of NTproCNP, T3 and CTx with other bone markers (PINP, osteocalcin, bALP) were weaker and reflected the latter's variable temporal responses after normal levels of thyroid hormones were restored (ie after 4-6 weeks). We conclude that, as in the immature skeleton, CNP production is linked to thyroid hormone levels in adults. The close coupling of T3, NTproCNP and CTx during changes in bone turnover suggests that CNP acts to maintain skeletal integrity in the face of T3-dependent bone resorption but participates less in later phases involving bone mineral accrual. (1) Hagiwara H et al., Am J Physiol 1996; 270:C1311-1318 (2) Prickett TC et al., Pediatr Res 2005; 58:334-340 (3) Reh CS et al., Program of the 91st Annual Meeting of the Endocrine Society, Washington, DC, 2009; Poster 03-342 Nothing to Disclose: BJS, TCP, PJH, MR, EAE
- Open Access
- 1 July 2009
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (7) , 2332-2337
FGF23 Elevation and Hypophosphatemia after Intravenous Iron Polymaltose: A Prospective Study
Context: Parenteral iron administration has been associated with hypophosphatemia. Fibroblast growth factor 23 (FGF23) has a physiological role in phosphate homeostasis via suppression of 25-hydroxyvitamin D [25(OH)D] activation and promotion of phosphaturia. We recently reported a case of iron-induced hypophosphatemic osteomalacia associated with marked FGF23 elevation. Objective: Our objective was to prospectively investigate the effect of parenteral iron polymaltose on phosphate homeostasis and to determine whether any observed change was related to alterations in circulating FGF23. Design, Setting, and Participants: Eight medical outpatients prescribed iv iron polymaltose were recruited. Plasma phosphate, 25(OH)D, 1,25-dihydroxyvitamin D [1,25(OH)2D], PTH, FGF23, and urinary tubular reabsorption of phosphate were measured prior to iron administration and then weekly for a minimum of 3 wk. Results: Plasma phosphate fell from 3.4 ± 0.6 mg/dl at baseline to 1.8 ± 0.6 mg/dl at wk 1 (P < 0.0001) associated with a fall in percentage tubular reabsorption of phosphate (90 ± 4.8 to 68 ± 13; P < 0.001) and 1,25(OH)2D (54 ± 25 to 9 ± 8 pg/ml; P < 0.001). These indices remained significantly suppressed at wk 2 and 3. 25(OH)D levels were unchanged. FGF23 increased significantly from 43.5 pg/ml at baseline to 177 pg/ml at wk 1 (P < 0.001) with levels correlating with both serum phosphate (R = −0.74; P 2D (R = −0.71; P < 0.05). Conclusion: Parenteral iron suppresses renal tubular phosphate reabsorption and 1α-hydroxylation of vitamin D resulting in hypophosphatemia. Our data suggest that this is mediated by an increase in FGF23.
- 1 July 2009
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (7) , 2332-2337
Open AccessFGF23 Elevation and Hypophosphatemia after Intravenous Iron Polymaltose: A Prospective Study
Context: Parenteral iron administration has been associated with hypophosphatemia. Fibroblast growth factor 23 (FGF23) has a physiological role in phosphate homeostasis via suppression of 25-hydroxyvitamin D [25(OH)D] activation and promotion of phosphaturia. We recently reported a case of iron-induced hypophosphatemic osteomalacia associated with marked FGF23 elevation. Objective: Our objective was to prospectively investigate the effect of parenteral iron polymaltose on phosphate homeostasis and to determine whether any observed change was related to alterations in circulating FGF23. Design, Setting, and Participants: Eight medical outpatients prescribed iv iron polymaltose were recruited. Plasma phosphate, 25(OH)D, 1,25-dihydroxyvitamin D [1,25(OH)2D], PTH, FGF23, and urinary tubular reabsorption of phosphate were measured prior to iron administration and then weekly for a minimum of 3 wk. Results: Plasma phosphate fell from 3.4 ± 0.6 mg/dl at baseline to 1.8 ± 0.6 mg/dl at wk 1 (P < 0.0001) associated with a fall in percentage tubular reabsorption of phosphate (90 ± 4.8 to 68 ± 13; P < 0.001) and 1,25(OH)2D (54 ± 25 to 9 ± 8 pg/ml; P < 0.001). These indices remained significantly suppressed at wk 2 and 3. 25(OH)D levels were unchanged. FGF23 increased significantly from 43.5 pg/ml at baseline to 177 pg/ml at wk 1 (P < 0.001) with levels correlating with both serum phosphate (R = −0.74; P 2D (R = −0.71; P < 0.05). Conclusion: Parenteral iron suppresses renal tubular phosphate reabsorption and 1α-hydroxylation of vitamin D resulting in hypophosphatemia. Our data suggest that this is mediated by an increase in FGF23.
- Open Access
- 22 January 2009
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 46 (2) , 167-169
Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia
Iron-induced renal phosphate wasting, hypophosphataemia and osteomalacia have previously been reported in a small number of Japanese patients receiving parenteral iron sucrose. We report the case history of a European male who, as a result of regular intravenous iron polymaltose, developed prolonged hypophosphataemia complicated by widespread insufficiency fractures. The pathogenesis of this complication remains unknown however our novel finding of a marked elevation in fibroblast growth factor 23 (FGF23), which normalized after ceasing parenteral iron, suggests an important and previously unreported effect of iron on FGF23 homeostasis.
- 22 January 2009
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 46 (2) , 167-169
Open AccessIron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia
Iron-induced renal phosphate wasting, hypophosphataemia and osteomalacia have previously been reported in a small number of Japanese patients receiving parenteral iron sucrose. We report the case history of a European male who, as a result of regular intravenous iron polymaltose, developed prolonged hypophosphataemia complicated by widespread insufficiency fractures. The pathogenesis of this complication remains unknown however our novel finding of a marked elevation in fibroblast growth factor 23 (FGF23), which normalized after ceasing parenteral iron, suggests an important and previously unreported effect of iron on FGF23 homeostasis.